Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 491

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 4
Chunk 491
---

     -  
     -  
     258,900  
     -  
     -  
     26,902 (5) 
     444,021 
  
    CFO 
    2023  
     165,000  
     88,475 (4) 
     -  
     282,215  
     -  
     -  
     5,934 (5) 
     541,624 

    (1)

    The
                                            amounts represent bonus earned as part of CEO Executive Scorecard

    (2)
    On
    December 6, 2024, Mr. Aminov was awarded an RSU Stock Award
  
    (3)
    Amount
    represents health insurance premiums paid, car payments, car insurance, and club memberships
  
    (4)
    
    Amount
                                            represents IPO bonus paid

    (5)
    Amounts
    represent health insurance premiums paid
  
    (6)
    The
    reported amounts represent the aggregate grant date fair value of the awards computed in accordance with Financial Accounting Standards
    Board Account Standards Codification Topic 718, Stock Compensation, as modified or supplemented, or FASB ASC Topic 718. The assumptions
    used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 8 to our Consolidated
    Financial Statements for the year ended December 31, 2024 included in this Report.

Narrative
Disclosure to Summary Compensation Table

Employment
Agreements

Except
as set forth below, we currently have no written employment agreements with any of our named executive officers.

Erez
Aminov

Effective
April 28, 2023, we entered into an employment agreement with Mr. Aminov, as amended on August 28, 2023, pursuant to which Mr. Aminov
will serve as our Chief Executive Officer. Under his employment agreement, as amended, Mr. Aminov has agreed to devote at least 50% of
his business time to the affairs of the Company. Mr. Aminov’s employment agreement provides that his employment will be on an at-will
basis and can be terminated by either Mr. Aminov or our company at any time and for any reason. Under the agreement, Mr. Aminov will
receive a base salary of $0.2 million per